logo
Innergex Announces the Voting Results From Its 2025 Annual and Special Meeting of Shareholders

Innergex Announces the Voting Results From Its 2025 Annual and Special Meeting of Shareholders

Globe and Mail02-05-2025
LONGUEUIL, QC , May 2, 2025 /CNW/ - Innergex Renewable Energy Inc. (TSX: INE) (" Innergex" or the " Corporation") is pleased to announce that (i) the holders of record on March 21, 2025 (the " Common Shareholders") of its common shares (the " Common Shares") and (ii) the holders of record on March 21, 2025 (the " Series A Preferred Shareholders") of its cumulative rate reset preferred shares, Series A (the " Series A Preferred Shares") have each approved, at the annual and special meeting of shareholders of the Corporation held on May 1 st, 2025 (the " Meeting"), a special resolution, in each case, approving the statutory plan of arrangement for the acquisition by CDPQ of (i) all of the issued and outstanding Common Shares (other than those held by CDPQ and its affiliates and the shares to be rolled over by certain members of senior management (collectively, the " Rollover Shareholders")) for a price of $13.75 per Common Share in cash and (ii) all of the issued and outstanding Series A Preferred Shares and cumulative redeemable fixed rate preferred shares, series C of Innergex (collectively with the Series A Preferred Shares, the " Preferred Shares") for a price of $25.00 per Preferred Share in cash (plus all accrued and unpaid dividends and, in the case of the Series A Preferred Shares, an amount in cash per Series A Preferred Share equal to the dividends that would have been payable in respect of such share until January 15, 2026 , which is the next available redemption date) (the " Arrangement").
At the Meeting, the arrangement resolution was approved by 99.86% of the votes cast by Common Shareholders present virtually or represented by proxy at the Meeting. The arrangement resolution was also approved by 99.86% of the votes cast by Common Shareholders present virtually or represented by proxy at the Meeting, excluding Common Shares held by the Rollover Shareholders and any other Common Shares required to be excluded pursuant to, in the province of Québec, Regulation 61-101 Respecting Protection of Minority Security Holders in Special Transactions and, in other provinces, Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions. The Series A Preferred Shareholders' arrangement resolution was approved by 99.86% of the votes cast by Series A Preferred Shareholders present virtually or represented by proxy at the Meeting.
The completion of the Arrangement remains subject to the satisfaction or waiver of certain other closing conditions customary in a transaction of this nature, including the receipt of a final order by the Québec Superior Court (the " Final Order") and certain regulatory approvals. The hearing in respect of the Final Order is scheduled to take place on May 7, 2025 . Assuming that these remaining conditions to closing are satisfied or waived, it is anticipated that the Arrangement will be completed by Q4 2025.
In addition to the two special resolutions regarding the Arrangement, the Corporation also announces that all nominees listed in the management information circular dated March 21, 2025 were elected as directors of the Corporation.
The detailed results of the vote by ballot of the Common Shares shareholders for the election of directors are as follows:
Votes For
% Votes For
Votes Against
% Votes Against
Marc-André Aubé
138,533,479
99.32
948,078
0.68
Pierre G. Brodeur
138,549,905
99.33
931,922
0.67
Radha D. Curpen
138,528,225
99.32
948,602
0.68
Nathalie Francisci
137,463,798
98.55
2,018,028
1.45
Richard Gagnon
127,045,725
91.08
12,436,102
8.92
Jean-Hugues Lafleur
137,349,685
98.47
2,132,142
1.53
Michel Letellier
138,532,062
99.32
949,765
0.68
Patrick Loulou
138,453,262
99.26
1,028,565
0.74
Monique Mercier
129,976,003
93.18
9,505,824
6.82
Ouma Sananikone
138,436,163
99.25
1,045,664
0.75
The formal report on voting results with respect to all matters voted upon during the Meeting was filed with the regulatory authorities and is available on SEDAR+ at www.sedarplus.ca.
Innergex plans to release its financial results for the three-month period ended March 31, 2025 , after market close on Wednesday, May 7, 2025 . In light of the Corporation's acquisition by CDPQ, no conference call is planned.
About Innergex Renewable Energy Inc.
For over 35 years, Innergex has believed in a world where abundant renewable energy promotes healthier communities and creates shared prosperity. As an independent renewable power producer which develops, acquires, owns and operates hydroelectric facilities, wind farms, solar farms and energy storage facilities, Innergex is convinced that generating power from renewable sources will lead the way to a better world. Innergex conducts operations in Canada , the United States , France and Chile and manages a large portfolio of high-quality assets currently consisting of interests in 90 operating facilities with an aggregate net installed capacity of 3,707 MW (gross 4 663 MW), including 42 hydroelectric facilities, 36 wind facilities, 9 solar facilities and 3 battery energy storage facilities. Innergex also holds interests in 17 projects under development with a net installed capacity of 945 MW (gross 1,577 MW), 6 of which are under construction, as well as prospective projects at different stages of development with an aggregate gross installed capacity totaling 10,288 MW. Its approach to building shareholder value is to generate sustainable cash flows and provide an attractive risk-adjusted return on invested capital.
To learn more, visit innergex.com or connect with us on LinkedIn.
Cautionary Statement Regarding Forward-Looking Information
To inform readers of the Corporation's future prospects, this press release contains forward-looking information within the meaning of applicable securities laws ("Forward-Looking Information"), including statements relating to the Arrangement, the ability to complete the Arrangement and the timing thereof, including the parties' ability to satisfy the conditions to the consummation of the Arrangement, the receipt of the required regulatory approvals and court approval and other customary closing conditions, the possibility of any termination of the arrangement agreement in accordance with its terms, and the expected benefits to the Corporation and its shareholders of the Arrangement, and other statements that are not historical facts. Forward-Looking Information can generally be identified by the use of words such as "approximately", "may", "will", "could", "believes", "expects", "intends", "should", "would", "plans", "potential", "project", "anticipates", "estimates", "scheduled" or "forecasts", or other comparable terms that state that certain events will or will not occur. It represents the projections and expectations of the Corporation relating to future events or results as of the date of this press release.
Risks and uncertainties related to the Arrangement include, but are not limited to: the possibility that the Arrangement will not be completed on the terms and conditions, or on the timing, currently contemplated, and that it may not be completed at all, due to a failure to obtain or satisfy, in a timely manner or otherwise, required regulatory and court approvals and other conditions to the closing of the Arrangement or for other reasons; the negative impact that the failure to complete the Arrangement for any reason could have on the price of the Corporation's securities or on its business; CDPQ's failure to pay the consideration at closing of the Arrangement; the failure to realize the expected benefits of the Arrangement; the restrictions imposed on the Corporation while the Arrangement is pending; the business of the Corporation may experience significant disruptions, including loss of clients or employees due to transaction-related uncertainty, industry conditions or other factors; risks relating to employee retention; the risk of regulatory changes that may materially impact the business or the operations of the Corporation; the risk that legal proceedings may be instituted against the Corporation; significant transaction costs or unknown liabilities; and risks related to the diversion of management's attention from the Corporation's ongoing business operations while the Arrangement is pending; and other risks and uncertainties affecting the Corporation. For more information on the risks and uncertainties, please refer to the "Forward-Looking Information" section of the Management's Discussion and Analysis for the year ended December 31, 2024 .
Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in Forward-Looking Information, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such Forward-Looking Information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. No forward-looking statement is a guarantee of future results. Accordingly, you should not place undue reliance on Forward-Looking Information, which speaks only as of the date made. The Forward-Looking Information contained in this press release represents the Corporation's expectations as of the date of this press release (or as the date they are otherwise stated to be made) and are subject to change after such date. However, the Corporation disclaims any intention or obligation or undertaking to update or revise any Forward-Looking Information whether as a result of new information, future events or otherwise, except as required under applicable securities laws. All of the Forward-Looking Information contained in this press release is expressly qualified by the foregoing cautionary statements.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

DRI Healthcare Announces Closing of Internalization Transaction
DRI Healthcare Announces Closing of Internalization Transaction

Cision Canada

time7 hours ago

  • Cision Canada

DRI Healthcare Announces Closing of Internalization Transaction

TORONTO, July 1, 2025 /CNW/ - DRI Healthcare Trust (TSX: (TSX: DHT.U) ("DRI Healthcare") today announced that it has completed its previously announced transaction to internalize its investment management function. "We are excited to complete this transaction and begin our next chapter as one integrated organization," said Gary Collins, Executive Chair of DRI Healthcare. "We believe that our new structure will lead to better strategic alignment of interests with unitholders and stronger governance with greater transparency, ultimately benefitting all stakeholders." "We have a strong and dedicated team, now entirely under the DRI Healthcare banner, aligned to invest in high-quality assets and build an industry leading portfolio," said Ali Hedayat, Chief Executive Officer of DRI Healthcare. "With a robust pipeline of strong growth prospects coupled with the newly reduced fee structure, we anticipate enhanced value generation as we continue growing the business over the long term." Transaction Terms As a result of the transaction, the management agreement with DRI Capital Inc. ("DRI Capital") was terminated in exchange for a $48 million termination payment (plus accrued management and performance fees), and the Trust internalized the manager function by acquiring the relevant assets of DRI Capital for a purchase price of $1 million. As a result of the transactions contemplated by the asset purchase agreement, the employees of DRI Capital also transitioned to a Trust subsidiary. DRI Capital also agreed to indemnify the Trust and its affiliates in respect of, among other things, damages relating to the previously disclosed irregularities related to certain alleged consulting and other expenses charged to DRI Healthcare. The transaction was recommended for approval by a special committee of the board composed of independent trustees (the "Special Committee"). In recommending the transaction, the Special Committee evaluated a number of alternatives, including maintaining the status quo, terminating the management agreement for cause, replacing DRI Capital with a new third-party manager, privatizing the Trust, and implementing an internalization transaction. About DRI Healthcare DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3.0 billion, acquiring more than 75 royalties on 45-plus drugs, including Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol " and in U.S. dollars under the symbol "DHT.U". To learn more, visit or follow us on LinkedIn. Caution concerning forward-looking statements This news release may contain forward-looking information within the meaning of applicable securities legislation. Forward-looking information can generally be identified by the use of words such as "expect", "continue", "anticipate", "intend", "aim", "plan", "believe", "budget", "estimate", "forecast", "foresee", "close to", "target" or negative versions thereof and similar expressions. Some of the specific forward-looking information in this news release may include, among other things, statements regarding the Trust's ability to execute on its strategy, the internalization of the Trust's manager and the terms and conditions, benefits and the value to be provided to unitholders. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Trust's control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, the risk that the internalization of the Trust's manager will not generate the levels of anticipated benefits for the Trust and its unitholders, and those additional risks and uncertainties that are disclosed in the Trust's most recent annual information form and under "Risk Factors" in the Trust's Management's Discussion and Analysis. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statements in this press release. You should not put undue reliance on forward-looking statements. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, the actual results, performance or achievements of the Trust could differ materially from the results expressed in, or implied by, any forward-looking statements. All forward-looking information in this news release speaks as of the date of this news release. The Trust does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise except as required by law. Additional information about these assumptions and risks and uncertainties is contained in the Trust's filings with securities regulators, including its latest annual information form and Management's Discussion and Analysis. These filings are also available at the Trust's website at

ImmunoGenesis Announces the Formation of Scientific Advisory Board
ImmunoGenesis Announces the Formation of Scientific Advisory Board

Cision Canada

time7 hours ago

  • Cision Canada

ImmunoGenesis Announces the Formation of Scientific Advisory Board

Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function designed to treat the many "immune-excluded" cancers that are resistant to existing immunotherapies HOUSTON, July 1, 2025 /CNW/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies is encouraged by the early performance of IMGS-001 in the ongoing Phase 1a dose escalation study in adult patients with locally advanced or metastatic solid tumors refractory to standard-of-care treatment. To advise on the clinical development strategy for IMGS-001 and other pipeline agents, the company is proud to announce the appointment of a six-member Scientific Advisory Board (SAB) who recently met to review our clinical data and provide input on the upcoming next phase of the IMGS-001 Phase 1a/1b study. "These distinguished members are true leaders in the field of immuno-oncology and come from some of the world's most prestigious cancer centers," said James Barlow, President and CEO of ImmunoGenesis. "I'm honored that the company can collaborate with this esteemed group of scientific and clinical experts whose insights will be instrumental in maximizing the potential of our lead agent to make a meaningful impact in treating some of the most challenging cancers." More details on the newly formed SAB are at the following link: About ImmunoGenesis ImmunoGenesis is a clinical-stage biotech company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic, dual-specific PD-L1/PD-L2 antibody currently in a Phase 1a/b clinical trial for the treatment of immune-excluded ("cold") tumors, which account for more than half of all cancers. In addition to its lead program, the company has a second clinical asset, IMGS-101 that has the potential to reverse tumor hypoxia, a major immunosuppressive element in solid tumors. The company has additional agents in the pipeline which represent novel approaches to overcome immune resistance in cold tumors. ImmunoGenesis designs therapies to address the pathology of these tumors, overcoming immune exclusion to elicit a robust immune response. For more information, visit About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor IMGS-001 is a PD-L1/PD-L2 dual-specific inhibitor with engineered cytotoxic effector function. It is the first molecule to target PD-L2 in addition to PD-L1, potentially shutting down the entire PD-1 pathway and providing a superior blockade compared to other PD-1 or PD-L1 inhibitors. Its engineered effector function enables IMGS-001 to kill immunosuppressive PD-L1- and/or PD-L2-expressing cells present in the tumor microenvironment, providing the potential to overcome immune resistance in immune-excluded tumors. Preclinical data showed that IMGS-001 drove superior survival rates and tumor growth inhibition in head-to-head studies compared to currently available immunotherapies. With its cytotoxic killing function and superior blockade, IMGS-001 may provide a new foundation for combination immuno-oncology therapies. This Phase 1a/b study is being conducted with support from an investment from the Cancer Focus Fund, LP and the Cancer Prevention and Research Institute of Texas (CPRIT) DP200094. Disclosures MD Anderson's relationship with ImmunoGenesis, and all research conducted at MD Anderson related to ImmunoGenesis, has been identified as an institutional financial conflict of interest by MD Anderson's Institutional Conflict of Interest Committee and is managed under an Institutional Conflict of Interest Management and Monitoring Plan. Dr. Curran and Dr. Hong receive compensation as members of the Immunogenesis SAB, and these financial relationships have been disclosed to MD Anderson's Conflict of Interest Committee in accordance with institutional policy. Contact ImmunoGenesis Investors: James Barlow President and CEO [email protected] SOURCE Immunogenesis Inc.

George Weston Limited Announces Timing of Second Quarter Earnings Release Français
George Weston Limited Announces Timing of Second Quarter Earnings Release Français

Cision Canada

time11 hours ago

  • Cision Canada

George Weston Limited Announces Timing of Second Quarter Earnings Release Français

TORONTO, July 1, 2025 /CNW/ - George Weston Limited (TSX: WN) announced today that it will release its second quarter 2025 results on July 29, 2025 at approximately 7:00AM (EDT). About George Weston Limited George Weston Limited is a Canadian public company founded in 1882. The Company operates through its two reportable operating segments, Loblaw Companies Limited and Choice Properties Real Estate Investment Trust. Loblaw provides Canadians with grocery, pharmacy, health and beauty, apparel, general merchandise, financial services and wireless mobile products and services. Choice Properties owns, manages and develops a high-quality portfolio of commercial and residential properties across Canada. SOURCE George Weston Limited

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store